An analyst doesn't think very highly of Axsome's prospects.
News & Analysis: Axsome Therapeutics
The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.
AXSM earnings call for the period ending June 30, 2020.
Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Are they still buys today?
One of the best investments of 2019 fell on hard times in the first six months of 2020, but it's not as bad as it seems.
Some traders appear to be taking profits off the table after the stock's jump last week.
Demand for Alzheimer's medication is expected to grow as the population of older adults rises.
The drugmaker received good news from the FDA for one of its pipeline candidates.
One big biotech and two small biotechs especially stand out as attractive picks.
The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?